

Evonik appoints Dr. Gaetano Blanda as new head of Animal Nutrition business line

6 September 2022

- New leader with over 20 years' experience in the chemical industry
- Track record and experience in digitalization, innovation, and business expansion
- Focus on sustainable nutrition and precision livestock farming

Main press contact

Yama Olumi

Head of Market Communications
Animal Nutrition
Phone + 49 6181 59-12437
yama.olumi@evonik.com

Alternative press contact

Dr. Jürgen Krauter

Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Essen, Germany. Evonik has appointed Dr. Gaetano Blanda as the new head of the Animal Nutrition business line. Gaetano Blanda, who was previously Senior Vice President and General Manager of Evonik's Coating Additives business line, will take over the role from Dr. Emmanuel Auer.

Evonik is one of the world's leading providers of feed ingredients and system solutions for efficient and healthy animal nutrition, with more than 50 years of experience in the livestock sector.

As head of the Animal Nutrition business line, Gaetano Blanda will be responsible for overseeing Evonik's amino acids and functional feed additives business and the expansion of its precision livestock farming approach, which is bringing data- and knowledge-based solutions to the livestock sector.

Gaetano Blanda brings to the role a strong track record and wealth of experience in digitalization, innovation, and business expansion, having successfully led the development of Evonik's Coating Additives business line since 2017.

Commenting on his appointment, Gaetano Blanda says: "I'm delighted to be taking the lead of Evonik's Animal Nutrition business line, with its great reputation in the animal nutrition and health industry and its relevance for the global food challenge. The world needs innovative solutions for a more sustainable livestock production that is in accordance with food safety, animal welfare, and limited natural resources. I look forward to continuing to build on the great work we're doing to improve livestock farming holistically."

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman

Executive Board

Christian Kullmann, Chairman

Dr. Harald Schwager, Deputy Chairman

Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Originally from a chemistry background, Gaetano Blanda has extensive knowledge in developing global business based on different business models and is looking forward to building on the company's portfolio of products and services in the poultry, swine, dairy, and aquaculture industries.

He was awarded a PhD from the University of Wuppertal, Germany, and the French National Centre for Scientific Research, and held a postdoctoral position at the Max Planck Institute. Gaetano Blanda also has a master's degree in marketing from St. Gallen School of Economics and completed an executive management program at the INSEAD Business School.

Gaetano Blanda has more than 20 years of experience in the chemical industry, working in various regions and markets including construction, plastics, textiles, agriculture, adhesives, and sealant. In 2017, he was appointed Senior Vice President, merging the various businesses of Evonik, Air Products Chemical Inc., and J. M. Huber Corporation to form the current Coating Additives business line.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.